Novartis Venture Fund

Founded 1996
Founders Argeris Karabelas


Unlock datapoints

Portfolio analytics



News & Media

Add fund to favorites
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 217
Average round size
The average size of a deal this fund participated in
Portfolio companies 125
Rounds per year 8.68
Lead investments 42
Follow on index
How often the fund supports its portfolio startups at next rounds
Exits 57
Key employees 5
Stages of investment
Early Stage Venture
Late Stage Venture

Areas of investment

  • Biotechnology
  • Health Care
  • Therapeutics
  • Medical
  • Pharmaceutical

In 1996 was created Novartis Venture Fund, which is appeared as VC. The main department of described VC is located in the Basel. The fund was located in Europe if to be more exact in Switzerland. Novartis Venture Fund appeared to be a CVC structure as part of the corporation.

The typical case for the fund is to invest in rounds with 5-6 participants. Despite the Novartis Venture Fund, startups are often financed by SV Health Investors, Apple Tree Partners, ARCH Venture Partners. The meaningful sponsors for the fund in investment in the same round are Versant Ventures, Venture Investors, Truffle Capital. In the next rounds fund is usually obtained by Sofinnova Investments, Astellas Venture Management, Venture Investors.

For fund there is no match between the country of its foundation and the country of its the most frequent investments - United States. Among the most successful fund investment fields, there are Medical Device, Life Science. Moreover, a startup needs to be at the age of 6-10 years to get the investment from the fund. Among the various public portfolio startups of the fund, we may underline Alios BioPharma, Merus, Catalyst Biosciences The fund has exact preference in some founders of portfolio startups. When startup sums 5+ of the founder, the probability for it to get the investment is little.

The fund was created by Argeris Karabelas. The overall number of key employees were 5.

The fund is constantly included in 7-12 deals per year. The usual things for fund are deals in the range of 10 - 50 millions dollars. This Novartis Venture Fund works on 4 percentage points less the average amount of lead investments comparing to the other organizations. The higher amount of exits for fund were in 2014. The high activity for fund was in 2009. Despite it in 2019 the fund had an activity. The real fund results show that this VC is 7 percentage points more often commits exit comparing to other companies. When the investment is from Novartis Venture Fund the average startup value is 10-50 millions dollars.

Read more

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation


$9M23 Nov 2021 London, England, United Kingdom

Kedalion Therapeutics

Health Care
15 Nov 2021 California, United States


Life Science
$157M11 Aug 2021 Seattle, Washington, United States

Artios Pharma

Medical Device
$150M27 Jul 2021 Cambridge, England, United Kingdom

Health Care
$42M17 May 2021 San Francisco, California, United States


Health Care
$57M04 May 2021 Iceland, Iceland

Amphista Therapeutics

$53M17 Mar 2021 Scotland

Faze Medicines

$81M10 Dec 2020 Cambridge, Massachusetts, United States

Rappta Therapeutics

Life Science
$10M13 Oct 2020 Uusimaa
Immunitas Therapeutics Closes $58M in Series B Financing

– Immunitas Therapeutics, a Waltham, MA-based single cell genomics-based therapeutics company, closed a $58m Series B financing.
– The round was led by Agent Capital with participation from Medical Excellence Capital (MEC), 120 Capital, Solasta Ventures, Mirae Asset, Ono Venture Investment, The Mark Foundation for Cancer Research, NS Investment, BrightEdge (American Cancer Society), and The Leukemia & Lymphoma Society . Existing investors Alexandria Venture Investments, Evotec, Leaps by Bayer, M Ventures, Novartis Venture Fund (NVF), and founding investor Longwood Fund also joined the round.
– The company intends to use the funds to advance its lead program, IMT-009, a CD161 inhibitor, into the clinic to treat both solid tumors and hematological malignancies.

GentiBio Raises $157M in Series A Financing

– GentiBio, Inc. from Boston develops engineered regulatory T cells (Tregs) therapies for immunology.
– Series A $157m round was led by Matrix Capital Management with participation from Avidity Partners, JDRF T1D Fund, OrbiMed, RA Capital Management, and Novartis Venture Fund.
– The company intends to use the funds to advance its potential functional cure for Type 1 Diabetes (T1D) to the clinic alongside multiple other pipeline programs in chronic autoimmunity and autoinflammation.


  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Novartis Venture Fund?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: